International journal of radiation oncology, biology, physics · 2026
Dose-Volume Predictors of Fatal Bronchopulmonary Bleeding After Stereotactic Body Radiation Therapy of Centrally Located Lung Tumors: An Analysis of the Expanded HILUS Cohort.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karlsson Kristin, Rancati Tiziana, Lindbäck Elias, Lindberg Sara, Grozman Vitali, Al-Jirf Karam, Lax Ingmar, Hoffmann Lone, Møller Ditte Sloth, Khalil Azza, Knap Marianne Marquard, Nielsen Tine Bjørn, Land Lotte Holm, Kristiansen Charlotte, Ramberg Christina, Rogg Lotte Victoria, Hagen Rebekka Knoph, Frøland Anne-Sofie, Drugge Ninni, Nyman Jan, Josipovic Mirjana, Persson Gitte Fredberg, Olofsson Jörgen, Bergström Per, Rosenbrand Hans-Olov, Lödén Britta, Haraldsson André, Engelholm Silke, Billiet Charlotte, Onjukka Eva, Lindberg Karin
Аннотация
PURPOSE: The expanded HILUS study showed that bronchial dose and bronchial tumor compression are risk factors for bronchopulmonary bleedings after stereotactic body radiation therapy of centrally located lung tumors. In the current analysis of the same cohort, the aim was to identify the dose-volume histogram (DVH) parameter that best predicts fatal bronchopulmonary bleeding and to develop a predictive model for this endpoint.
METHODS AND MATERIALS: The HILUS cohort included 230 patients with 238 central targets treated with stereotactic body radiation therapy of 7 Gy × 8 to the periphery of the planning target volume, where 21 patients developed grade-5 bronchopulmonary bleeding. Cox regression-based normal-tissue complication probability models were developed, accounting for the dose to the main and intermediate bronchi and bronchial tumor compression. Three alternative DVH parameters were explored: the dose to a certain volume (Dv), the volume receiving a certain dose (Vd), and the equivalent uniform dose. Internal validation was performed with the bootstrap method.
RESULTS: The best fits of the bivariable normal-tissue complication probability models included bronchial tumor compression in combination with the DVH parameters of D0.31 cm3, V82Gy,EQD2 (equivalent dose in 2-Gy fractions), and equivalent uniform dose with n = 0.024, respectively. This indicates that a high dose to a small volume may lead to grade-5 bronchopulmonary bleeding. The probability of fatal bleeding at 2 years without bronchial tumor compression was 10% for a D0.31 cm3 of 107 Gy3 EQD2, and 20% at 165 Gy3 EQD2, whereas the probability with bronchial tumor compression was 10% at 0 Gy3 and 20% at 58 Gy3 EQD2. The model showed good discrimination and calibration.
CONCLUSIONS: Bronchial tumor compression is a strong predictor for grade-5 bleeding, and the most relevant dose parameter appears to be the dose to a small volume of the main and intermediate bronchi.
METHODS AND MATERIALS: The HILUS cohort included 230 patients with 238 central targets treated with stereotactic body radiation therapy of 7 Gy × 8 to the periphery of the planning target volume, where 21 patients developed grade-5 bronchopulmonary bleeding. Cox regression-based normal-tissue complication probability models were developed, accounting for the dose to the main and intermediate bronchi and bronchial tumor compression. Three alternative DVH parameters were explored: the dose to a certain volume (Dv), the volume receiving a certain dose (Vd), and the equivalent uniform dose. Internal validation was performed with the bootstrap method.
RESULTS: The best fits of the bivariable normal-tissue complication probability models included bronchial tumor compression in combination with the DVH parameters of D0.31 cm3, V82Gy,EQD2 (equivalent dose in 2-Gy fractions), and equivalent uniform dose with n = 0.024, respectively. This indicates that a high dose to a small volume may lead to grade-5 bronchopulmonary bleeding. The probability of fatal bleeding at 2 years without bronchial tumor compression was 10% for a D0.31 cm3 of 107 Gy3 EQD2, and 20% at 165 Gy3 EQD2, whereas the probability with bronchial tumor compression was 10% at 0 Gy3 and 20% at 58 Gy3 EQD2. The model showed good discrimination and calibration.
CONCLUSIONS: Bronchial tumor compression is a strong predictor for grade-5 bleeding, and the most relevant dose parameter appears to be the dose to a small volume of the main and intermediate bronchi.